Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II.


Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN: 1527-7755
Titre abrégé: J Clin Oncol
Pays: United States
ID NLM: 8309333

Informations de publication

Date de publication:
10 11 2021
Historique:
pubmed: 26 8 2021
medline: 21 12 2021
entrez: 25 8 2021
Statut: ppublish

Résumé

The Groningen International Study on Sentinel nodes in Vulvar cancer (GROINSS-V)-II investigated whether inguinofemoral radiotherapy is a safe alternative to inguinofemoral lymphadenectomy (IFL) in vulvar cancer patients with a metastatic sentinel node (SN). GROINSS-V-II was a prospective multicenter phase-II single-arm treatment trial, including patients with early-stage vulvar cancer (diameter < 4 cm) without signs of lymph node involvement at imaging, who had primary surgical treatment (local excision with SN biopsy). Where the SN was involved (metastasis of any size), inguinofemoral radiotherapy was given (50 Gy). The primary end point was isolated groin recurrence rate at 24 months. Stopping rules were defined for the occurrence of groin recurrences. From December 2005 until October 2016, 1,535 eligible patients were registered. The SN showed metastasis in 322 (21.0%) patients. In June 2010, with 91 SN-positive patients included, the stopping rule was activated because the isolated groin recurrence rate in this group went above our predefined threshold. Among 10 patients with an isolated groin recurrence, nine had SN metastases > 2 mm and/or extracapsular spread. The protocol was amended so that those with SN macrometastases (> 2 mm) underwent standard of care (IFL), whereas patients with SN micrometastases (≤ 2 mm) continued to receive inguinofemoral radiotherapy. Among 160 patients with SN micrometastases, 126 received inguinofemoral radiotherapy, with an ipsilateral isolated groin recurrence rate at 2 years of 1.6%. Among 162 patients with SN macrometastases, the isolated groin recurrence rate at 2 years was 22% in those who underwent radiotherapy, and 6.9% in those who underwent IFL ( Inguinofemoral radiotherapy is a safe alternative for IFL in patients with SN micrometastases, with minimal morbidity. For patients with SN macrometastasis, radiotherapy with a total dose of 50 Gy resulted in more isolated groin recurrences compared with IFL.

Identifiants

pubmed: 34432481
doi: 10.1200/JCO.21.00006
pmc: PMC8577685
doi:

Types de publication

Clinical Trial, Phase II Comparative Study Journal Article Multicenter Study Research Support, Non-U.S. Gov't Webcast

Langues

eng

Sous-ensembles de citation

IM

Pagination

3623-3632

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016058
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA233193
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA233331
Pays : United States

Commentaires et corrections

Type : CommentIn

Références

Gynecol Oncol. 2014 Dec;135(3):583-5
pubmed: 25128606
Clin Oncol (R Coll Radiol). 2007 Sep;19(7):542-50
pubmed: 17624745
Gynecol Oncol. 2017 Sep;146(3):580-587
pubmed: 28687171
Gynecol Oncol. 2020 Feb;156(2):467-474
pubmed: 31837831
Int J Radiat Oncol Biol Phys. 2016 Jul 15;95(4):1191-200
pubmed: 27130794
J Clin Oncol. 2012 Nov 1;30(31):3786-91
pubmed: 22753905
J Clin Oncol. 2008 Feb 20;26(6):884-9
pubmed: 18281661
Lancet Oncol. 2010 Jul;11(7):646-52
pubmed: 20537946
Gynecol Oncol. 2015 Jun;137(3):365-72
pubmed: 25868965

Auteurs

Maaike H M Oonk (MHM)

University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

Brian Slomovitz (B)

Mount Sinai Medical Center, Miami Beach, FL.

Peter J W Baldwin (PJW)

Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.

Helena C van Doorn (HC)

Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.

Jacobus van der Velden (J)

Amsterdam University Medical Center, Amsterdam, the Netherlands.

Joanne A de Hullu (JA)

Radboud University Medical Center, Nijmegen, the Netherlands.

Katja N Gaarenstroom (KN)

Leiden University Medical Center, Leiden, the Netherlands.

Brigitte F M Slangen (BFM)

Maastricht University Medical Center+, Maastricht, the Netherlands.

Ignace Vergote (I)

Leuven Cancer Institute, Leuven, Belgium.

Mats Brännström (M)

Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden.

Eleonora B L van Dorst (EBL)

University Medical Center Utrecht, Utrecht, the Netherlands.

Willemien J van Driel (WJ)

Center of Gynecological Oncology Amsterdam, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

Ralph H Hermans (RH)

Catharina Ziekenhuis Eindhoven, the Netherlands.

David Nunns (D)

Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom.

Martin Widschwendter (M)

UCL EGA Institute for Women's Health, University College London, London, United Kingdom.

David Nugent (D)

Leeds Teaching Hospitals NHS Trust, St James' University Hospital, Leeds, United Kingdom.

Cathrine M Holland (CM)

Manchester University NHS Foundation Trust-St Marys Hospital, Manchester, United Kingdom.

Aarti Sharma (A)

University Hospital of Wales, Cardiff, United Kingdom.

Paul A DiSilvestro (PA)

Women and Infants Hospital of Rhode Island, Providence, RI.

Robert Mannel (R)

Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK.

Dorry Boll (D)

Catharina Ziekenhuis Eindhoven, the Netherlands.

David Cibula (D)

First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.

Al Covens (A)

University of Toronto, Toronto, Ontario, Canada.

Diane Provencher (D)

CHUM, Université de Montréal, Montréal, Quebec, Canada.

Ingo B Runnebaum (IB)

Jena University Hospital, Friedrich Schiller University, Jena, Germany.

David Luesley (D)

University of Birmingham, Birmingham, United Kingdom.

Patricia Ellis (P)

Royal Surrey NHS Foundation Trust, Guildford, United Kingdom.

Timothy J Duncan (TJ)

Norfolk and Norwich University Hospital NHS Trust, Norwich, United Kingdom.

Ming Y Tjiong (MY)

Amsterdam University Medical Center, Amsterdam, the Netherlands.

Derek J Cruickshank (DJ)

James Cook University Hospital, South Tees NHS Foundation Trust, Middlesbrough, United Kingdom.

Preben Kjølhede (P)

Linköping University, Linköping, Sweden.

Charles F Levenback (CF)

MD Anderson Cancer Center, Houston, TX.

Jiri Bouda (J)

University Hospital Pilsen, Charles University, Faculty of Medicine, Pilsen, Czech Republic.

Katharina E Kieser (KE)

Dalhousie University, Halifax, Nova Scotia, Canada.

Connie Palle (C)

Capio, Part of Ramsey Santé, Hellerup, Denmark.

Nicola M Spirtos (NM)

Women's Cancer Center of Nevada, Las Vegas, NV.

David M O'Malley (DM)

Ohio State University Comprehensive Cancer Center-James Cancer Hospital, Columbus, OH.

Mario M Leitao (MM)

Memorial Sloan Kettering Cancer Center, New York, NY.

Melissa A Geller (MA)

University of Minnesota, Minneapolis, MN.

Kalyan Dhar (K)

Singleton Hospital, Swansea, United Kingdom.

Viren Asher (V)

University Hospitals of Derby and Burton, Derby, United Kingdom.

Karl Tamussino (K)

Medical University Graz, Graz, Austria.

Daniel H Tobias (DH)

Morristown Medical Center, Morristown, NJ.

Christer Borgfeldt (C)

Skåne University Hospital, Lund University, Lund, Sweden.

Jayanthi S Lea (JS)

UT Southwestern Medical Center, Dallas, TX.

Jo Bailey (J)

St Michaels Hospital, Bristol, United Kingdom.

Margareta Lood (M)

Central Hospital Karlstad, Karlstad, Sweden.

Brynhildur Eyjolfsdottir (B)

Oslo University Hospital, Radiumhospitalet, Oslo, Norway.

Stephen Attard-Montalto (S)

West Kent Cancer Centre, Maidstone Hospital, Maidstone, United Kingdom.

Krishnansu S Tewari (KS)

UC Irvine Health Medical Center, Orange, CA.

Ranjit Manchanda (R)

Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom.

Pernille T Jensen (PT)

Aarhus University Hospital, Aarhus, Denmark.

Par Persson (P)

Uppsala University, Uppsala, Sweden.

Linda Van Le (L)

University of North Carolina, Chapel Hill, NC.

Hein Putter (H)

Leiden University Medical Center, Leiden, the Netherlands.

Geertruida H de Bock (GH)

University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

Bradley J Monk (BJ)

St Josephs Hospital and Medical Center, Phoenix, AZ.

Carien L Creutzberg (CL)

Leiden University Medical Center, Leiden, the Netherlands.

Ate G J van der Zee (AGJ)

University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH